Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01607710

Acronym

fMRI

Enrollment

Registered

2012-05-30

Start date

2012-07-31

Completion date

2014-06-30

Last updated

2014-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Keywords

fMRI, Generalized Anxiety Disorder

Brief summary

The investigators are seeking to locate the brain regions of interest in generalized anxiety disorder (GAD) using both structural (sMRI) and functional magnetic resonance imaging (fMRI). The MRI will be used to measure changes in blood flow in the brain while at rest and while completing tasks designed to elicit symptoms of anxiety. Results from a nonclinical control group and a GAD group will be compared to determine whether they exhibit different areas of brain activity during the tasks.

Detailed description

20 healthy controls and 20 participants with GAD will be recruited. Each participant will undergo an MRI session that will last approximately 2 hours. The structural MRI will be used when the participant is at rest. During the functional MRI (fMRI), a computer screen inside the scanner will display four tasks the participant must complete: (1)Gambling Task, (2)Risk & Ambiguity Task, (3)Reading Emotion from the Eyes (REE) Task, and (4)Emotional Counting Task.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Generalized Anxiety Disorder(GAD)Group: Inclusion Criteria: * Clinical diagnosis of Generalized Anxiety Disorder * Hamilton Anxiety Rating Scale score of 18 or higher * Hamilton Rating Scale for Depression score of 17 or less * Fluency in English * Capacity to understand the nature of the study and willingness to sign informed consent for

Exclusion criteria

* History of epilepsy or head trauma (Loss of consciousness\>5 minutes) with the past 6 months * Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis or brain surgery * A review of patient medications by the study physician indicates an increased risk of seizure * An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency * Substance use disorder or posttraumatic stress disorder (PTSD) within the past 6 months * Lifetime bipolar disorder, obsessive-compulsive disorder (OCD), psychotic disorder, mental retardation, or pervasive development disorder * Any psychotic features, including dementia or delirium * Medication change within past 3 months * Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months * Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study * Any contraindication for participation in MRI scan Nonclinical Control Group: Inclusion Criteria: * Absence of any psychiatric diagnosis

Design outcomes

Primary

Measure	Time frame	Description
Brain activation while undergoing the fMRI	Throughout the fMRI	Main effects for each condition will be calculated to elucidate brain activations relevant to the tasks. Random effect 2 sample t-tests will assess group differences (i.e., GAD patients vs. healthy controls) to identify regions that demonstrate hyperactivation in patients.

Countries

United States

Outcome results